OBJECTIVES: To evaluate the performance of multiparametric MRI (MP-MRI) in predicting CaP on repeat biopsy; and to compare the cancer detection rates (CDR) of MRI/TRUS fusion-guided biopsy with standard 12-core biopsy in men with at least one previous negative biopsy.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
MATERIALS AND METHODS: We prospectively enrolled men with elevated or rising PSA and/or abnormal DRE into our MRI/TRUS fusion-guided prostate biopsy trial. Participants underwent a 3T MP-MRI with an endorectal coil. Three radiologists graded all suspicious lesions on a 5-point Likert scale. MRI/TRUS fusion-guided biopsies of suspicious prostate lesions and standard TRUS-guided 12-core biopsies were performed. Analysis of 140 eligible men with at least one previous negative biopsy was performed. We calculated CDR and estimated area under curves (AUCs) of MP-MRI in predicting any and clinically significant CaP.
RESULTS: The overall CDR was 65.0% (91/140). Higher level of suspicion on MP-MRI was significantly associated with prostate cancer detection (p< 0.001) with an AUC of 0.744 compared with 0.653 and 0.680 for PSA and PSA density respectively. The CDRs of MRI/TRUS fusion-guided and standard 12-core biopsy modalities were 52.1% (73/140) and 48.6% (68/140) respectively (p = 0.435). However, fusion biopsy was more likely to detect clinically significant CaP when compared with the 12-core modality (47.9% vs. 30.7%; p < 0.001). Of the cancers missed by 12-core, 20.9% (19/91) were clinically significant. Most cancers missed by 12-core (69.6%) were located in the anterior fibromuscular stroma and central gland. Using a Fusion biopsy only approach in men with an MRI suspicion score of ≥ 4 would have missed only 3.5% of clinically significant CaP.
CONCLUSIONS: MP-MRI and subsequent MRI/TRUS fusion-guided biopsy platform may improve detection of clinically significant CaP in men with previous negative biopsies. Addition of a 12-core biopsy may be needed to avoid missing some clinically significant CaP.
Salami SS, Ben-Levi E, Yaskiv O, Ryniker L, Turkbey B, Kavoussi LR, Villani R, Rastinehad AR. Are you the author?
The Arthur Smith Institute for Urology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY 11042.
Reference: BJU Int. 2014 Sep 23. Epub ahead of print.